News|Articles|November 16, 2026

Journal Digest: November 16

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • Chronic hand eczema prevalence was 9.6% in US adults, peaking above 13% in ages 18 to 39 and higher in men, employed, and urban populations.
  • Cancer incidence was increased versus general population in morphea (SIR 1.24) and systemic sclerosis (SIR 1.37), with hematologic excess confined to systemic sclerosis.
SHOW MORE

Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.

JAMA Dermatology | Prevalence of Chronic Hand Eczema in Adults

A cross-sectional study of 10,636 US adults evaluated the prevalence of health care professional–diagnosed chronic hand eczema (CHE), defined by persistent disease lasting at least 3 months or recurrent flares. Overall, 1019 participants (9.6%) reported a CHE diagnosis. Prevalence was higher among men than women (10.5% vs 8.7%), employed than unemployed adults (10.3% vs 7.8%), and urban than rural residents (10.4% vs 6.3%). Adults aged 18 to 39 years demonstrated particularly high prevalence, exceeding 13% across the 18-to-29 and 30-to-39 age groups.

For dermatology clinicians, the findings highlight the substantial burden of CHE and the importance of recognizing persistent or recurrent hand dermatitis in routine practice. Because prevalence estimates relied on self-reported professional diagnoses, the findings may not fully capture undiagnosed disease or distinguish among underlying etiologies. Additional research may help clarify the impact of occupational exposures, demographic factors, and barriers to diagnosis.1

JAMA Dermatology | Incidence of Cancer in Morphea and Systemic Sclerosis

A population-based cohort study evaluated cancer incidence among 6181 patients with morphea and 8133 patients with systemic sclerosis (SSc). During follow-up, cancer developed in 782 patients with morphea (12.65%) and 1104 patients with SSc (13.57%). Compared with the general population, overall cancer incidence was elevated in both groups, with standardized incidence ratios of 1.24 for morphea and 1.37 for SSc. Solid tumor incidence was increased in both cohorts, whereas hematologic cancer incidence was significantly elevated only among patients with SSc. Cancer patterns also differed, with female reproductive and breast cancers predominating in morphea and lung cancer most frequently observed in SSc.

For clinicians, the findings suggest that malignancy risk may warrant consideration in patients with morphea, despite its predominantly cutaneous presentation. However, the observational design does not establish a causal relationship between either condition and cancer development, and the results do not independently support intensified screening beyond established recommendations. Further research is needed to identify patients who may benefit from more individualized cancer surveillance.2

JAMA Dermatology | Clinical Characteristics, Etiologic Associations, and Treatment Outcomes of Pernio

A research letter examined the clinical characteristics, potential etiologic associations, and treatment outcomes of patients with pernio, an inflammatory acral condition commonly associated with exposure to cold and damp environments. Although pernio frequently presents as a self-limited condition, similar lesions may occur in association with autoimmune disorders and other systemic diseases. The investigation explored differences in clinical presentation and management across patients with varying underlying associations.

For dermatology clinicians, the research highlights the importance of distinguishing idiopathic pernio from potentially secondary disease, particularly in patients with recurrent, persistent, or atypical lesions. Clinical history, examination findings, and associated symptoms remain important considerations when determining whether additional evaluation is warranted. The research-letter format and limited outcome information available for review restrict conclusions regarding comparative treatment effectiveness.3

JAMA Dermatology | End-of-Dose Effect as a Guide for Biologic Optimization in Hidradenitis Suppurativa

A cohort study of 107 patients with hidradenitis suppurativa (HS) who demonstrated partial responses to biologic therapy examined whether symptom recurrence near the end of a dosing interval could guide treatment optimization. Patients experiencing an end-of-dose effect (EODE), characterized by worsening symptoms before their next scheduled biologic dose, underwent dose intensification. Those without an EODE received adjunctive long-term antibiotic therapy. The response-pattern–guided approach was associated with improvements across 7 prespecified clinical outcomes at 3 to 5 months, with benefits sustained through 6 to 12 months.

For dermatology clinicians, the findings suggest that the timing of symptom recurrence may provide a practical consideration when managing incomplete biologic responses in HS. Distinguishing potential waning drug exposure from persistent inflammatory activity could help inform individualized treatment discussions. However, because treatment allocation was based on clinical response patterns rather than randomization, prospective controlled studies are needed to determine whether this approach improves outcomes compared with other optimization strategies.4

JAMA Dermatology | Evaluating the Performance of Melanoma Risk Prediction Models

A prognostic study evaluated the performance of 6 melanoma risk prediction models using data from up to 43,235 participants in Australia's Sax Institute 45 and Up Study. Investigators assessed discrimination, or the ability to distinguish individuals who subsequently developed melanoma from those who did not, alongside calibration, which measures agreement between predicted and observed risk. Across the models, areas under the receiver operating characteristic curve ranged from 0.58 to 0.70, indicating variable discriminatory performance. Most models underestimated melanoma risk in the evaluated population.

For dermatology clinicians, the findings underscore the importance of external validation before incorporating melanoma risk prediction tools into clinical decision-making. Although risk models may help inform prevention counseling and surveillance discussions, differences in population characteristics and baseline melanoma incidence can affect their accuracy. The results suggest that recalibration and further validation may be necessary before these models can reliably guide individualized risk assessment.5

References

  1. Chovatiya R, Balu S, Bin Sawad A, et al. Prevalence of chronic hand eczema in adults. JAMA Dermatol. Published online November 11, 2026. doi:10.1001/jamadermatol.2026.4674.
  2. Muha J, Joly-Chevrier M, Nedjar H, et al. Incidence of cancer in morphea and systemic sclerosis. JAMA Dermatol. Published online November 11, 2026. doi:10.1001/jamadermatol.2026.4685.
  3. Martins K, Ristianto ZA, Manduca S, et al. Clinical characteristics, etiologic associations, and treatment outcomes of pernio. JAMA Dermatol. Published online November 11, 2026. doi:10.1001/jamadermatol.2026.4339.
  4. Lynch A, Archimbaud J, Lesort C, et al. End-of-dose effect as a guide for biologic optimization in hidradenitis suppurativa. JAMA Dermatol. Published online November 4, 2026. doi:10.1001/jamadermatol.2026.4435.
  5. Evaluating the performance of melanoma risk prediction models. JAMA Dermatol. Published online October 21, 2026. doi:10.1001/jamadermatol.2026.4097.


Related to this article